139 research outputs found
Technical note:On the reliability of laboratory beta-source calibration for luminescence dating
The dose rate of the 90Sr / 90Y beta source used in most
luminescence readers is a laboratory key parameter. There is a
well-established body of knowledge about parameters controlling accuracy and
precision of the calibration value but some hard-to-explain inconsistencies
still exist. Here, we have investigated the impact of grain size, aliquot
size and irradiation geometry on the resulting calibration value through
experiments and simulations. The resulting data indicate that the dose rate
of an individual beta source results from the interplay of a number of
parameters, most of which are well established by previous studies. Our
study provides evidence for the impact of aliquot size on the absorbed dose
in particular for grain sizes of 50–200 µm. For this grain-size
fraction, the absorbed dose is enhanced by ∼ 10 %–20 % as
aliquot size decreases due to the radial increase of dose rate towards
the centre of the aliquot. The enhancement is most variable for 50–100 µm
grains mounted as aliquots of < 8 mm size. The enhancement is
reversed when large grains are mounted as small aliquots due to the edge
effect by which the dose induced by backscattered electrons is reduced.
While the build-up of charge dictates the increase of absorbed dose with the
increase of grain size, this principle becomes more variable with changing
irradiation geometry. We conclude that future calibration samples should
consist of subsamples composed of small, medium, large and very large quartz
grains, each obtaining several gamma doses. The calibration value measured
with small, medium and large aliquots is then obtained from the inverse
slope of the fitted line, not from a single data point. In this way, all
possible irradiation geometries of an individual beta source are covered,
and the precision of the calibration is improved.</p
Metal-insulator transitions in anisotropic 2d systems
Several phenomena related to the critical behaviour of non-interacting
electrons in a disordered 2d tight-binding system with a magnetic field are
studied. Localization lengths, critical exponents and density of states are
computed using transfer matrix techniques. Scaling functions of isotropic
systems are recovered once the dimension of the system in each direction is
chosen proportional to the localization length. It is also found that the
critical point is independent of the propagation direction, and that the
critical exponents for the localization length for both propagating directions
are equal to that of the isotropic system (approximately 7/3). We also
calculate the critical value of the scaling function for both the isotropic and
the anisotropic system. It is found that the isotropic value equals the
geometric mean of the two anisotropic values. Detailed numerical studies of the
density of states for the isotropic system reveals that for an appreciable
amount of disorder the critical energy is off the band center.Comment: 6 pages RevTeX, 6 figures included, submitted to Physical Review
Dimensional Crossover of Weak Localization in a Magnetic Field
We study the dimensional crossover of weak localization in strongly
anisotropic systems. This crossover from three-dimensional behavior to an
effective lower dimensional system is triggered by increasing temperature if
the phase coherence length gets shorter than the lattice spacing . A similar
effect occurs in a magnetic field if the magnetic length becomes shorter
than , where \D_{||}/D_\perp is the ratio of the
diffusion coefficients parallel and perpendicular to the planes or chains.
depends on the direction of the magnetic field, e.g. or
1/2 for a magnetic field parallel or perpendicular to the planes in a quasi
two-dimensional system. We show that even in the limit of large magnetic field,
weak localization is not fully suppressed in a lattice system. Experimental
implications are discussed in detail.Comment: RevTeX, 11 pages, 4 figures; three references added and discusse
Grand Challenges (and Great Opportunities) in Sedimentology, Stratigraphy, and Diagenesis Research
No abstract available
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in intermediate- and advanced-stage children and adolescents with classic Hodgkin lymphoma: a titration study with an embedded non-inferiority randomised controlled trial
BACKGROUND: Children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma achieve an event-free survival at 5 years of about 90% after treatment with vincristine, etoposide, prednisone, and doxorubicin (OEPA) followed by cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) and radiotherapy, but long-term treatment effects affect survival and quality of life. We aimed to investigate whether radiotherapy can be omitted in patients with morphological and metabolic adequate response to OEPA and whether modified consolidation chemotherapy reduces gonadotoxicity. METHODS: Our study was designed as a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial, and was carried out at 186 hospital sites across 16 European countries. Children and adolescents with newly diagnosed intermediate-stage (treatment group 2) and advanced-stage (treatment group 3) classical Hodgkin lymphoma who were younger than 18 years and stratified according to risk using Ann Arbor disease stages IIAE, IIB, IIBE, IIIA, IIIAE, IIIB, IIIBE, and all stages IV (A, B, AE, and BE) were included in the study. Patients with early disease (treatment group 1) were excluded from this analysis. All patients were treated with two cycles of OEPA (1·5 mg/m(2) vincristine taken intravenously capped at 2 mg, on days 1, 8, and 15; 125 mg/m(2) etoposide taken intravenously on days 1–5; 60 mg/m(2) prednisone taken orally on days 1–15; and 40 mg/m(2) doxorubicin taken intravenously on days 1 and 15). Patients were randomly assigned to two (treatment group 2) or four (treatment group 3) cycles of COPP (500 mg/m(2) cyclophosphamide taken intravenously on days 1 and 8; 1·5 mg/m(2) vincristine taken intravenously capped at 2 mg, on days 1 and 8; 40 mg/m(2) prednisone taken orally on days 1 to 15; and 100 mg/m(2) procarbazine taken orally on days 1 to 15) or COPDAC, which was identical to COPP except that 250 mg/m(2) dacarbazine administered intravenously on days 1 to 3 replaced procarbazine. The method of randomisation (1:1) was minimisation with stochastic component and was centrally stratified by treatment group, country, trial sites, and sex. The primary endpoint was event-free survival, defined as time from treatment start until the first of the following events: death from any cause, progression or relapse of classical Hodgkin lymphoma, or occurrence of secondary malignancy. The primary objectives were maintaining 90% event-free survival at 5 years in patients with adequate response to OEPA treated without radiotherapy and to exclude a decrease of 8% in event-free survival at 5 years in the embedded COPDAC versus COPP randomisation to show non-inferiority of COPDAC. Efficacy analyses are reported per protocol and safety in the intention-to-treat population. The trial is registered with ClinicalTrials.gov (trial number NCT00433459) and EUDRACT (trial number 2006-000995-33), and is closed to recruitment. FINDINGS: Between Jan 31, 2007, and Jan 30, 2013, 2102 patients were recruited. 737 (35%) of the 2102 recruited patients were in treatment group 1 (early-stage disease) and were not included in our analysis. 1365 (65%) of the 2102 patients were in treatment group 2 (intermediate-stage disease; n=455) and treatment group 3 (advanced-stage disease; n=910). Of these 1365, 1287 (94%) patients (435 [34%] of 1287 in treatment group 2 and 852 [66%] of 1287 in treatment group 3) were included in the titration trial per-protocol analysis. 937 (69%) of 1365 patients were randomly assigned to COPP (n=471) or COPDAC (n=466) in the embedded trial. Median follow-up was 66·5 months (IQR 62·7–71·7). Of 1287 patients in the per-protocol group, 514 (40%) had an adequate response to treatment and were not treated with radiotherapy (215 [49%] of 435 in treatment group 2 and 299 [35%] of 852 in treatment group 3). 773 (60%) of 1287 patients with inadequate response were scheduled for radiotherapy (220 [51%] of 435 in the treatment group 2 and 553 [65%] of 852 in treatment group 3. In patients who responded adequately, event-free survival rates at 5 years were 90·1% (95% CI 87·5–92·7). event-free survival rates at 5 years in 892 patients who were randomly assigned to treatment and analysed per protocol were 89·9% (95% CI 87·1–92·8) for COPP (n=444) versus 86·1% (82·9–89·4) for COPDAC (n=448). The COPDAC minus COPP difference in event-free survival at 5 years was −3·7% (−8·0 to 0·6). The most common grade 3–4 adverse events (intention-to-treat population) were decreased haemoglobin (205 [15%] of 1365 patients during OEPA vs 37 [7%] of 528 treated with COPP vs 20 [2%] of 819 treated with COPDAC), decreased white blood cells (815 [60%] vs 231 [44%] vs 84 [10%]), and decreased neutrophils (1160 [85%] vs 223 [42%] vs 174 [21%]). One patient in treatment group 2 died of sepsis after the first cycle of OEPA; no other treatment-related deaths occurred. INTERPRETATION: Our results show that radiotherapy can be omitted in patients who adequately respond to treatment, when consolidated with COPP or COPDAC. COPDAC might be less effective, but is substantially less gonadotoxic than COPP. A high proportion of patients could therefore be spared radiotherapy, eventually reducing the late effects of treatment. With more refined criteria for response assessment, the number of patients who receive radiotherapy will be further decreased. FUNDING: Deutsche Krebshilfe, Elternverein für Krebs-und leukämiekranke Kinder Gießen, Kinderkrebsstiftung Mainz, Tour der Hoffnung, Menschen für Kinder, Programme Hospitalier de Recherche Clinique, and Cancer Research UK
Sea level and climate changes during OIS 5e in the Western Mediterranean
Palaeontological, geomorphological and sedimentological data supported by isotopic dating on Oxygen
Isotopic Stage (OIS) 5e deposits from the Spanish Mediterranean coast, are interpreted with the aim of
reconstructing climatic instability in the Northern Hemisphere. Data point to marked climatic instability
during the Last Interglacial (OIS 5e), with a change in meteorological conditions and, consequently, in the
sedimentary environment. The oolitic facies generated during the first part of OIS 5e (ca. 135 kyr) shift into
reddish conglomeratic facies during the second part (ca. 117 kyr). Sea surface Temperature (SST) and salinity
are interpreted mainly on the basis of warm Senegalese fauna, which show chronological and spatial
differential distribution throughout the Western Mediterranean. Present hydrological and meteorological
conditions are used also as modern analogues to reconstruct climatic variability throughout the Last
Interglacial, and this variability is interpreted within the wider framework of the North Atlantic record. All
the available data indicate an increase in storminess induced by an increase in the influence of northwesterlies,
a slight drop of SST in the northern Western Mediterranean, and an important change in
meteorological conditions at the end of OIS 5e (117 kyr). These changes correlate well with the decrease in
summer insolation and with the climatic instability recorded in North Atlantic high latitudes
Are publicly available internet resources enabling women to make informed fertility preservation decisions before starting cancer treatment: an environmental scan?
Background To identify publicly available internet resources and assess their likelihood to support women making informed decisions about, and between, fertility preservation procedures before starting their cancer treatment. Methods A survey of publically available internet resources utilising an environmental scan method. Inclusion criteria were applied to hits from searches of three data sources (November 2015; repeated June 2017): Google (Chrome) for patient resources; repositories for clinical guidelines and projects; distribution email lists to contact patient decision aid experts. The Data Extraction Sheet applied to eligible resources elicited: resource characteristics; informed and shared decision making components; engagement health services. Results Four thousand eight hundred fifty one records were identified; 24 patient resources and 0 clinical guidelines met scan inclusion criteria. Most resources aimed to inform women with cancer about fertility preservation procedures and infertility treatment options, but not decision making between options. There was a lack of consistency about how health conditions, decision problems and treatment options were described, and resources were difficult to understand. Conclusions Unless developed as part of a patient decision aid project, resources did not include components to support proactively women’s fertility preservation decisions. Current guidelines help people deliver information relevant to treatment options within a single disease pathway; we identified five additional components for patient decision aid checklists to support more effectively people’s treatment decision making across health pathways, linking current with future health problems
- …